More than half of clinical studies fail to post results

Researchers conducting applicable clinical trials are required to post their study results within one year, but compliance with this requirement is very poor, according to a new study published in The Lancet.

Sponsors of applicable trials are required to report trial results online to ClinicalTrials.gov within a year of completion.

Not reporting clinical trial results can have a negative impact, by distorting the evidence base for the clinical practice, break ethical obligations between researchers and participants and simply waste research resources. The final rule went into effect January 20018.

Researchers downloaded data for all registered trials on the government website on a monthly basis from March 2018 to September 2019, including all applicable trials due to report results under the law.

Of those analyzed, 4,209 trials were supposed to post their results, but only 1,722 did so within the one-year deadline, the study found. That’s only 41%, and about one-third of the trials, or 1,523, didn’t report at all as of Sept. 16, 2019. The median delay was 424 days––59 days longer than the legal requirement of one year.

Since July 2018, compliance also did not improve, the researchers noted. However, industry sponsors were more likely to post their trial results within the one-year deadline compared to non-industry, non-government sponsors. In addition, sponsors with large numbers of trials were “significantly” more likely to comply with the requirement than smaller sponsors, researchers found.

“Poor compliance is likely to reflect lack of enforcement by regulators,” wrote first author Nicholas J DeVito MPH, of the University of Oxford un the U.K., and colleagues. “Effective enforcement and action from sponsors is needed; until then, open public audit of compliance for each individual sponsor may help.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.